What is Trastuzumab?

For the adjuvant treatment of HER2-overexpressing breast cancer, Trastuzumab is indicated in several clinical settings as part of a regimen consisting of doxorubicin, cyclophosphamide, and paclitaxel or docetaxel, as part of a regimen consisting of docetaxel and carboplatin, or as monotherapy after multimodal anthracycline therapy.

Trastuzumab is used in combination with paclitaxel for the first-line treatment of metastatic breast cancer that overexpresses HER2. It can also be used as a monotherapy in patients with metastatic breast cancer who have previously received one or more chemotherapy regimens. It can also be used in combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received previous treatment for metastatic disease. Trastuzumab can be made into a powder for intravenous infusion (drip) or subcutaneous injection, and is administered in combination with hyaluronidase or hyaluronidase and pertuzumab for the treatment of HER2-positive adult breast cancer.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. Trastuzumab original drug has also been launched overseas. The ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, please consult the medical consultant. Currently, there are no generic trastuzumab drugs on the market.